<p>Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study</p>
OncoTargets and Therapy2020Vol. Volume 13, pp. 12683–12693
Citations Over TimeTop 10% of 2020 papers
Guosheng Yuan, Xiao Cheng, Qi Li, Mengya Zang, Wei Huang, Wenzhe Fan, Tao Wu, Jian Ruan, Wencong Dai, Wenxuan Yu, Mian Chen, Yabing Guo, Xiao Hu, Jinzhang Chen
Abstract
Camrelizumab and apatinib yielded a promising outcome in patients with advanced HCC who developed a tumor thrombus in the first lower-order portal vein branches and was generally safe and had manageable side effects.
Related Papers
- → Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients(2016)30 cited
- → 1250P Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017)(2022)11 cited
- → Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review(2020)13 cited
- → Apatinib in advanced alveolar soft part sarcoma: Evidence of efficacy and safety.(2018)
- → P3.01-49 Effciency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma(2018)